Objective: Describe baseline patient characteristics, needs, and stress of new to insulin at hospital discharge.

Methods: Single site RCT to evaluate a DM Discharge Toolkit on mean 30-day glucose is ongoing among English speaking patients (pts), 21 - 80 years, with expected survival > 90 days, new to insulin at discharge.

Results: Among 97 eligible, 67 approached, and 40 enrolled (consent rate 60%). Mean age was 51.9 years +11.4; 55% were male; 35% had public insurance; 52% identified as black, 30% white, and >22% Hispanic/Latino, with 23 (58%) prior DM. Mean glucose was 374 <u>+</u>213 and median HbA1C 11.4 [9.6, 13.3]. Nearly 30% had limited literacy (Single Item Literacy Screener, >2), though > 90% had home internet and reported its use for health information. Acceptability of research continuous glucose meter (CGM) at discharge was high (48%). Stress was also high, over 60% reported elevated perceived stress (Perceived Stress Scale <u>></u>14), 35% with prior DM reported elevated DM distress (Diabetes Distress Score <u>> </u>2.0). A majority (60%) had <u>></u> 1 health-related social need (HRSN), 12.5% had > 3; food insecurity (22.5%), transportation (15%) and medication affordability (12.5%) were highest.

Conclusion: Our medically/socially complex cohort of DM patients consented to RCT, including many of minority race/ethnicity. These patients have high levels of disease and non-disease specific stress and multiple HRSN that could affect safe insulin delivery. Interestingly, most accessed and used technology/internet, and were open to DM technology (CGM). Achieving better glycemic control in our sickest patients demands comprehensive, multi-modal interventions which can leverage DM technology to enhance care delivery.

Disclosure

K. Lee: None. C.M. Smyrniotis: None. C.A. Clingan: None. K.M.V. Carthy: None. C. Coventry: None. K. Davis: None. S.J. Freeman: None. J.J. Lee: None. J. Song: None. J.L. Holl: None. S. Bailey: Consultant; Gilead Sciences, Inc. Research Support; Gilead Sciences, Inc., Pfizer Inc., Merck Sharp & Dohme Corp., Lundbeck. Consultant; Lundbeck. A. Wallia: Research Support; UnitedHealth Group, Novo Nordisk.

Funding

R18 HS026143, NIH/AHRQ

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.